S-1: Canopy Growth Files for Resale of 16.3 Million Common Shares
S-1 Filing
Canopy Growth Corporation has filed a registration statement for the resale of up to 16,317,020 common shares by selling securityholders following a private placement.
Summary
- Canopy Growth Corporation has filed a Form S-1 registration statement with the SEC to allow selling securityholders to resell up to 16,317,020 common shares.
- These shares consist of 8,158,510 common shares, 1,909,600 common shares underlying Series A Warrants, and 6,248,910 common shares underlying Series B Warrants.
- The shares and warrants were issued in a private placement on January 19, 2024, where 8,158,510 units were sold at $4.29 per unit.
- Each unit included one common share and either a Series A or Series B warrant, both exercisable at US$4.83 per share.
- Series A Warrants are exercisable from January 19, 2024, to January 19, 2029, while Series B Warrants are exercisable from July 19, 2024, to July 19, 2029.
- Canopy Growth will not receive any proceeds from the resale of shares by the selling securityholders.
- However, if the warrants are fully exercised for cash, Canopy Growth would receive approximately US$39.4 million, which would be used to pay down debt and for general corporate purposes.
- As of January 25, 2024, Canopy Growth's common shares closed at US$4.65 on the Nasdaq Global Select Market.
- As of January 22, 2024, there were 91,113,912 common shares issued and outstanding.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing is a procedural step for a previously announced private placement. While the potential warrant exercises could benefit the company, there's no guarantee they will occur.
Positives
- Potential debt reduction: The exercise of warrants could generate approximately US$39.4 million for Canopy Growth, which would be used to pay down debt.
- Increased working capital: Proceeds from warrant exercises could also be used for working capital and other general corporate purposes.
Negatives
- No proceeds from resale: Canopy Growth will not receive any proceeds from the resale of shares by the selling securityholders.
- Uncertain warrant exercise: There is no assurance that any of the warrants will be exercised.
Risks
- High degree of risk: Investing in Canopy Growth's common shares involves a high degree of risk, as detailed in the risk factors section of the prospectus and incorporated documents.
- Volatility: The trading price of common shares could decline due to various risks, potentially leading to a loss of investment.
- Market conditions: The selling securityholders may sell shares at varying prices, which could be influenced by market conditions.
Future Outlook
The company may be impacted by forward-looking statements regarding future operations, business plans, business and investment strategies and the performance of investments, which are subject to risks and uncertainties.
Industry Context
The document does not provide specific details on how this announcement relates to broader industry trends or competitors within the cannabis and consumer packaged goods (CPG) sectors.
Stakeholder Impact
- Shareholders: Existing shareholders may experience dilution if the warrants are exercised and new shares are issued.
- Selling Securityholders: The selling securityholders are given the opportunity to sell their shares publicly.
Next Steps
- The selling securityholders may offer and sell the shares covered by the prospectus from time to time.
- The company may receive proceeds if the warrants are exercised.
Key Dates
| Date | Description |
|---|---|
| October 1, 2019 | Date of the Unanimous Shareholders Agreement by and among the Company, BioSteel and the BioSteel Shareholders party thereto, as amended. |
| February 23, 2021 | Completion date of the plan of arrangement involving RIV Capital Inc. |
| June 22, 2021 | Completion date of the plan of arrangement with The Supreme Cannabis Company, Inc. |
| March 31, 2023 | End of Canopy Growth's fiscal year. |
| June 22, 2023 | Date of KPMG LLP's report on the consolidated financial statements of Canopy Growth Corporation. |
| July 13, 2023 | Date the Company entered into separate, privately negotiated redemption agreements with certain holders of the Companys 4.25% senior notes due 2023. |
| July 14, 2023 | Date an aggregate of 90,196,657 Redemption Shares were issued to the July 2023 Noteholders. |
| July 17, 2023 | Date an aggregate of 234,263 Redemption Shares were issued. |
| September 18, 2023 | The Company entered into the subscription agreements with certain investors. |
| December 15, 2023 | Effective date of the Consolidation of the Companys issued and outstanding Common Shares. |
| January 9, 2024 | The Company entered into subscription agreements with certain investors for a private placement of units. |
| January 12, 2024 | The January 9 Private Placement did not close and was terminated by mutual agreement of the Company and the January 9 Investors. |
| January 18, 2024 | Date of the Subscription Agreements with the Selling Securityholders. |
| January 19, 2024 | Date of the Private Placement; Series A Warrants exercisable from this date. |
| January 22, 2024 | Date used for beneficial ownership calculations; 91,113,912 Common Shares outstanding as of this date. |
| January 25, 2024 | Closing price of Common Shares on Nasdaq was US$4.65; Date of Certificate of Compliance. |
| January 26, 2024 | Date of the S-1 filing. |
| July 19, 2024 | Series B Warrants exercisable from this date. |
| January 19, 2029 | End date for exercising Series A Warrants. |
| July 19, 2029 | End date for exercising Series B Warrants. |
Keywords
common shares, warrants, resale, private placement, Canopy Growth, securities, registration, offering, selling securityholders, cannabis
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.